Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
The SELECT-GCA study demonstrated 46% of patients with giant cell arteritis (GCA) treated with 15 mg upadacitinib plus a 26-233k steroid taper regimen were able to achieve sustained remission from week 12 through week 52, according to a press release from …